搜索范围
32097
应用筛选条件
关键词:'32097'
显示 1-30 共 45 条结果 关于 "32097" 范围 论文
Jody K Takemoto et al.
Clinical pharmacokinetics, 47(11), 703-720 (2008-10-09)
The NSAID etoricoxib is a selective inhibitor of cyclo-oxygenase 2 (COX-2), approved for treatment of patients with chronic arthropathies and musculoskeletal and dental pain. The rate of absorption of etoricoxib is moderate when given orally (the maximum plasma drug concentration
I L Meek et al.
European journal of clinical pharmacology, 69(3), 365-371 (2012-08-15)
Nonsteroidal anti-inflammatory drugs (NSAIDs) and acetylsalicylic acid (ASA) are often prescribed concurrently in patients with nociceptive pain and cardiovascular comorbidity. NSAIDs and ASA inhibit the same COX-enzymes, and thus may interact. ASA's cardioprotective antiplatelet effect is entirely COX-1 dependent. NSAIDs
V Dahl et al.
Acta anaesthesiologica Scandinavica, 56(1), 95-101 (2011-11-23)
Many studies have demonstrated that either COX-2 antagonists or glucocorticoids are efficient analgesics after orthopaedic surgery. We wanted to evaluate if the combination of these two drugs was better than one drug alone when added to paracetamol, local anaesthesia, and
B Renner et al.
European journal of pain (London, England), 16(6), 838-848 (2012-02-18)
Administering cyclooxygenase-2 inhibitors preoperatively appears attractive since these drugs reduce post-operative pain, but do not increase the risk of post-operative bleeds, asthmatic attacks and stress-related gastrointestinal ulcers. In a former investigation, we could show that post-operative administration of etoricoxib reduces
Peter Lierz et al.
Acta orthopaedica, 83(6), 642-647 (2012-11-13)
BACKGROUND AND PURPOSE Analgesics can have undesirable effects. We assessed whether a single preoperative dose of 120 mg etoricoxib reduces the need for additional opioids after therapeutic arthroscopic knee surgery. METHODS A double-blind, placebo-controlled study was performed at a single
Beate Mayer et al.
Transfusion, 53(5), 1033-1036 (2012-08-14)
Etoricoxib, a selective inhibitor of cyclooxygenase 2, is increasingly used in pain relief. Here, we report the first case of etoricoxib-induced immune hemolytic anemia. An 84-year-old male patient developed anemia 1 week after treatment with etoricoxib. There was no evidence
Neeti Nadda et al.
Molecular and cellular biochemistry, 372(1-2), 101-112 (2012-09-20)
This study explored the role of pro- and anti-inflammatory cytokines in dimethyl benz(a)anthracene (DMBA)-induced lung cancer and its subsequent correction with a COX-2 inhibitory NSAID, etoricoxib. A single dose of DMBA (20 mg/kg body weight) in 0.9 % NaCl administered
Shruti Setia et al.
Molecular and cellular biochemistry, 366(1-2), 89-99 (2012-03-14)
Roles of cyclooxygenase (COX) enzyme and intrinsic pathway of apoptosis have been explored for the chemopreventive effects of non-steroidal anti-inflammatory drugs (NSAIDs) on 9,10-dimethyl benz(a)anthracene (DMBA)-induced lung cancer in rat model. 16 weeks after the administration of DMBA, morphological analysis
Shaunta' D Martina et al.
The Annals of pharmacotherapy, 39(5), 854-862 (2005-04-14)
To review the available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of etoricoxib, a highly selective cyclooxygenase-2 (COX-2) inhibitor that is not currently approved for use in the US. Literature retrieval was accessed through MEDLINE (1966-December 2004)
Bahadir Suleyman et al.
International immunopharmacology, 23(1), 179-185 (2014-07-30)
The purpose of this study was to investigate the effect of etoricoxib on oxidative injury induced with ischemia-reperfusion (I/R) in rat kidney tissue in terms of biochemistry and immunohistochemistry. Male Albino Wistar rats were divided into renal I/R (RIR), 50
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF
Health Technology Assessment (Winchester, England), 12(11), 1-278 (2008)
Shruti Setia et al.
Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer, 31(1), 27-37 (2012-05-18)
9,10-Dimethyl benz(a)anthracene (DMBA), when injected intratracheally once at a dose of 20 mg/kg body weight, is found to induce lung cancer in rats. Two nonsteroidal anti-inflammatory drugs (NSAIDs), indomethacin and etoricoxib, are given orally daily as chemopreventive agents at a
Lisa Zimmer et al.
Archives of dermatology, 148(3), 357-361 (2012-01-18)
Painful lobular panniculitis appears to be a novel cutaneous adverse effect of selective BRAF inhibitors. We report the clinical course and management in 2 women with metastatic melanomas harboring the BRAF(V600E) mutation, who developed panniculitis with arthralgia during therapy with
L I Alekseeva
Terapevticheskii arkhiv, 82(8), 57-62 (2010-09-29)
The review gives and analyzes the data of a number of studies evaluating the safety and efficacy of nonsteroidal anti-inflammatory drugs on the upper gastrointestinal tract. Particular emphasis is laid on the results of the multinational etoricoxib and diclofenac arthritis
Klaus Schaffler et al.
British journal of clinical pharmacology, 75(2), 404-414 (2012-07-11)
Laser (radiant-heat) evoked potentials (LEPs) from vertex-EEG peak-to-peak (PtP) amplitude were used to determine acute antinociceptive/antihyperalgesic efficacy of ABT-102, a novel TRPV1 antagonist efficacious in preclinical pain models, compared with active controls and placebo in normal and UV(B)-inflamed skin. This
Sanjiv Kumar et al.
Acta poloniae pharmaceutica, 68(6), 839-843 (2011-12-01)
A simple, reproducible and efficient reverse phase high performance liquid chromatographic method was developed for simultaneous estimation of etoricoxib and thiocolchicoside in combined tablet dosage form. Formulation containing etoricoxib and thiocolchicoside is used as analgesic. Chromatography was performed on a
Deborah J Cochrane et al.
Drugs, 62(18), 2637-2651 (2002-12-06)
Etoricoxib is a cyclo-oxygenase (COX)-2-selective NSAID with a higher COX-1 to COX-2 selectivity ratio than the other COX-2-selective NSAIDs rofecoxib, valdecoxib or celecoxib. In patients with rheumatoid arthritis, improvements in tender and swollen joint counts and patient and investigator global
Rita Citraro et al.
Brain research bulletin, 113, 1-7 (2015-02-24)
Different data suggest the involvement of specific inflammatory pathways in the pathogenesis of epilepsy. Cyclooxygenase (COX), which catalyses the production of pro-inflammatory prostaglandins, may play a significant role in seizure-induced neuroinflammation and neuronal hyperexcitability. COX-2 is constitutively expressed in the
Shruti Setia et al.
Molecular and cellular biochemistry, 369(1-2), 75-86 (2012-07-04)
Non-steroidal anti-inflammatory drugs (NSAIDs) are emerging as novel chemopreventive agents against a variety of cancers owing to their capability in blocking the tumor development by cellular proliferation, angiogenesis and by promoting apoptosis. The present study further explored the comparative role
Shashi Srivastava et al.
Middle East journal of anaesthesiology, 21(5), 725-730 (2012-12-26)
Etoricoxib, a selective Cox-2 inhibitor has been found to be effective in the management of acute pain. This study evaluates the effect of preoperative use of oral Etoricoxib on post operative pain relief and sleep in patients undergoing single level
[Effective pain management after hallux valgus correction].
Elke Mertens
Pflege Zeitschrift, 65(6), 339-339 (2012-06-30)
M Hasanuzzaman Shohag et al.
Arzneimittel-Forschung, 61(11), 617-621 (2012-01-12)
The aim of this study was to compare the pharmacokinetic properties of two etoricoxib (CAS 202409-33-4) 60 mg formulations, namely Etocox-60 (test product) and reference product, and to evaluate whether these two formulations meet the FDA criteria to assume bioequivalence.
Yuhong Yuan et al.
Current pharmaceutical design, 13(22), 2237-2247 (2007-08-21)
Cyclo-oxygenase (COX)-2 selective inhibitors (coxibs) were designed to reduce the incidence of gastrointestinal (GI) adverse events (AEs) which occur with non-selective NSAIDs (ns-NSAIDs). Etoricoxib and lumiracoxib are regarded as second generation coxibs because of their higher COX-2 selectivity. There are
Myung Chul Yoo et al.
Current medical research and opinion, 30(12), 2399-2408 (2014-08-19)
We evaluated the COX-2 inhibitors, etoricoxib and celecoxib, in Korean patients with osteoarthritis (OA). This study included patients (≥ 40 years of age) with a clinical and radiographic diagnosis of knee OA. Patients were randomized to etoricoxib 30 mg (qd)
P Leclercq et al.
Revue medicale de Liege, 59(5), 345-349 (2004-07-24)
Etoricoxib (Arcoxia) is a novel non steroidal anti-inflammatory drug (NSAID) that selectively inhibits the inducible form of cyclo-oxygenase (COX), COX-2. Etoricoxib has a higher COX-1/COX-2 selectivity ratio than the other COX-2-selective NSAIDs as rofecoxib, valdecoxib or celecoxib. Tablets of 60
Katherine F Croom et al.
Drugs, 69(11), 1513-1532 (2009-07-29)
Etoricoxib is a selective cyclo-oxygenase (COX)-2 inhibitor, approved in Europe for the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis. Etoricoxib provided similar symptomatic relief to nonselective NSAIDs in patients with these conditions, and to celecoxib
E Chilet-Rosell et al.
Journal of public health (Oxford, England), 31(3), 434-445 (2009-03-17)
The aim of this study was to determine compliance with published good practice guidelines for gender and clinical trials using etoricoxib. The rationale for choosing etoricoxib was that it is widely used by women and there is evidence of potential
Tilman T Zittel et al.
Diseases of the colon and rectum, 56(6), 761-767 (2013-05-09)
Cyclo-oxygenase 2 inhibitors can be used for pain treatment after colorectal surgery. The aim of this study was to investigate whether the use of etoricoxib has negative effects on the perioperative outcome in colorectal surgery. Complication data from an advanced
Sarah Aldington et al.
The New Zealand medical journal, 118(1223), U1684-U1684 (2005-10-15)
To determine the risk of thromboembolic cardiovascular events associated with the use of etoricoxib, a COX-2 inhibitor. Systematic review and meta-analysis of placebo-controlled randomised double-blind clinical trials of etoricoxib that were of at least 6 weeks duration and presented data
Shruti Setia et al.
Pharmacological reports : PR, 64(3), 615-624 (2012-07-21)
Non-steroidal anti-inflammatory drugs (NSAIDs) act by inhibition of cyclooxygenase-2 (COX-2), which is overexpressed in cancer. The role of COX-2 and apoptosis were evaluated in 9,10-dimethylbenz(a)anthracene (DMBA)-induced lung cancer in rat and chemoprevention with indomethacin, a traditional NSAID and etoricoxib, a
1/2